| Prev Close | 2.36 |
| Open | 2.35 |
| Day Low/High | 2.34 / 2.41 |
| 52 Wk Low/High | 2.96 / 25.60 |
| Volume | 1.07M |
| Avg Volume | 1.86M |
| Exchange | NASDAQ |
| Shares Outstanding | 125.10M |
| Market Cap | 297.75M |
| EPS | -1.30 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
Celldex Therapeutics Presents Phase 1 Study Of Varlilumab And Opdivo® At 2017 ASCO Annual Meeting
Early signs of clinical activity without increased toxicity observed
Celldex Presents Promising Overall Survival Data From Phase 2 Study Of Single-agent Glembatumumab Vedotin In Patients With Checkpoint-Refractory Metastatic Melanoma
Combination study with checkpoint inhibitor currently enrolling; data from combination arm with varlilumab anticipated in fall of 2017
First Week Of November 17th Options Trading For Celldex Therapeutics (CLDX)
Investors in Celldex Therapeutics, Inc. saw new options begin trading this week, for the November 17th expiration.
Celldex Provides Corporate Update And Reports Full Year 2016 Results
Conference Call Scheduled for 4:30 p.m. ET Today
First Week of CLDX March 17th Options Trading
Investors in Celldex Therapeutics, Inc. saw new options become available this week, for the March 17th expiration.
What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016
TheStreet's biotech columnist offers his own report card on biotech stocks.
2016 Was a Terrible Year for Biotech but the Tweets Were on Point
A look back at the year's worth of Adam Feuerstein's biotech tweets.
Celldex Presents Data On CDX-1140, A Novel CD40 Agonist Antibody For Hematologic And Solid Malignancies, At The American Society Of Hematology (ASH) Annual Meeting
Additional investigator-sponsored presentations on varlilumab, CDX-301 and CDX-1401 also at ASH
Commit To Buy Celldex Therapeutics At $3, Earn 23.3% Using Options
Investors considering a purchase of Celldex Therapeutics, Inc. shares, but cautious about paying the going market price of $4.17/share, might benefit from considering selling puts among the alternative strategies at their disposal.
Corbus Pharma Bear Thesis Is Alive and Well on Sclerosis Drug Data Skewed Positive
The imbalances in patient baseline characteristics provided an assist to Corbus' resunab treatment response and undermines the credibility of the trial results, a source says.
Celldex Expands Antibody And Immuno-Oncology Portfolio With The Acquisition Of Kolltan Pharmaceuticals
--Conference call to be held at 4:30 p.m. Eastern Time today--
Phase 2 Study Of Single-agent Glembatumumab Vedotin In Patients With Checkpoint-Refractory Metastatic Melanoma Meets Primary Overall Response Endpoint And Demonstrates Clinically Meaningful Duration Of Response
Combination study with checkpoint inhibitor planned; combination arm with varlilumab currently enrolling
Celldex Therapeutics (CLDX) Stock Up on Q2 Results
Celldex Therapeutics (CLDX) reported a narrower loss than analysts had anticipated for the 2016 second quarter after Monday's closing bell.
Celldex Therapeutics (CLDX) Is Strong On High Volume Today
Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a strong on high relative volume candidate
Celldex Reports Second Quarter 2016 Results
Conference Call Scheduled for Monday, August 8 at 4:30 p.m. Eastern Time
